Inhibrx Biosciences, Inc. (INBX)

USD 14.09

(-3.16%)

Market Cap (In USD)

203.96 Million

Revenue (In USD)

1.8 Million

Net Income (In USD)

-241.36 Million

Avg. Volume

128.18 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
10.8-18.95
PE
-
EPS
-
Beta Value
2.877
ISIN
US45720L1070
CUSIP
45720L107
CIK
1739614
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Mark Paul Lappe
Employee Count
-
Website
https://inhibrx.com
Ipo Date
2024-06-04
Details
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.